“We have spent the last 70 years using and misusing antibiotics to treat and prevent common infectious diseases…It is therefore imperative that non-antibiotic solutions to fight infections are developed in order to preserve the next generation of effective medicine.”
Carolyn Cross Inducted Onto Board of IPA
Our CEO has done it again. Two weeks after being featured in the Vancouver Sun Newspaper, Ms. Cross has now been inducted onto the Board of the International Photodynamic Association (IPA). Founded in 1986, the IPA brings together the most distinguished international clinicians and scientists involved in researching and developing photodynamic therapy. Ms. Cross will help raise awareness about the benefits of this technology and help bring it to the forefront of medicine.
We are very pleased to share this announcement with all of you today. Ms. Cross has been with Ondine for over a decade and was one of the initial founders and financial supporters of our company. Under her leadership, Ondine has developed a rapid R & D program and is now seen as one of the world’s most renowned group of experts on photodynamic therapy and photodisinfection. Read More
Today, we celebrate our first blogging milestone – our 100th post. It’s incredible to see how far we have come, and exciting to imagine where we soon will be. You, the readers and followers of Ondine’s blogs, have played the central role in getting us here; your encouraging words, insightful comments, and guest blog posts have helped us tremendously throughout this process. Thank you so much.
Our goal has always been to make important points in bite-sized, digestible sound bites for today’s fast paced world. Our first one hundred posts have helped lay the foundation for this, and our next steps involve creating more engaging, relevant and compelling content. This will come in the form of videos, graphics, testimonials and case studies from the field.
Carolyn Cross, Chairman & CEO of Ondine Biomedical Inc, understands too well the importance of supporting women in business. This week, the Vancouver Sun Newspaper highlighted her involvement & support for this week’s Women Presidents’ Organization (WPO) International Conference. This is a unique event that connects highly successful women from around the world in promoting the advancement of women across all industries. The WPO is an exclusive membership organization for women presidents of multimillion-dollar companies. Collectively, members of the WPO have 24,000 years in business, generate $14 billion in annual revenues, and employ 105,000 employees.
Carolyn Cross, Chairman & CEO of Ondine Biomedical Inc, was featured in today's Vancouver Sun Newspaper
Last Friday, we announced an innovative partnership with Vancouver General Hospital (VGH), one of Canada`s largest hospitals. Today, we are very excited to have this partnership featured on Global News.
MRSAidTM is a non-antibiotic therapy designed to eliminate bacteria in the noses of patients during high infection risk times. Pathogenic bacteria such asStaphylococcus aureus and MRSA can significantly increase the risk of a patient developing serious infections after surgery. As part of our partnership with VGH, MRSAidTMwill be used on patients undergoing cardiac, spinal, breast reconstruction, thoracic, neurological, and orthopaedic surgeries. We are very excited to be working with the leaders in infection control at VGH. For more information on MRSAidTM, please visit www.mrsaid.com. Also, connect with us on Twitter & Facebook, we`ll be happy to respond to any of your comments and questions.
World Health Day is celebrated on the 7th of April every year to mark the establishment of the World Health Organization (WHO). Each year, the WHO selects a key health issue and encourages people from around the world to hold events and promote actions that will improve health. It is very fitting for Ondine then that this year’s World Health Day theme is “Combating Drug Resistance.” We have spent the last 70 years using and misusing antibiotics to treat and prevent common infectious diseases. Today, we have entered an era where bacteria have developed the ability to become resistant to most antibiotics, rendering them almost useless. It is therefore imperative that non-antibiotic solutions to fight infections are developed in order to preserve the next generation of effective medicine. Read More
The key features of aPDT can be summarized as follows [1]:
Broad spectrum of action, since one photosensitizer can act on bacteria, fungi, yeasts and parasitic protozoa
Efficacy independent of the resistance pattern of the given microbe
Extensive reduction of pathogen counts in minutes, without damaging host cells
No selection of resistant strains after multiple treatments
Readily available, non-toxic photosensitizers
Relatively low-cost light sources for activation of the photosensitizing agent
No cytotoxic effects on key sensitive host cells such as human keratinocytes or fibroblasts
The treatment of topical infections has traditionally relied upon antibiotics in either topical or systemic dosage forms. However, the inexorable increase in antibiotic resistance (including to vancomycin and other glycopeptides) has led to the spectre of potentially untreatable infections, and this in turn has led to the development of alternative antimicrobial approaches based on light-activated chemotherapy 2, 3. Photodynamic Disinfection (called antimicrobial PDT by the scientific community) is an extension to traditional photodynamic therapy (PDT) which was originally focused on oncotherapy and intra-ocular indications, utilizing systemically-administered photosensitizers. Read More
Today we announced a significant new opportunity for both our company and for the Photodynamic Therapy (PDT) world. By awarding our groups a £ 1 million award to develop PDT based products to prevent catheter associated infections, the UK Government has validated the need for solutions as well as endorsed the potential of Photodynamic Therapy in this role.
Together with a team of multi-disciplined experts at University College London (UCL), Ondine will collaborate on an important new initiative which leverages our combined 30 plus years of history in photodynamics to develop a new major class of medical devices based on Photodynamic disinfection. The new class of products will address the multi-billion dollar issue of catheter-associated infections, firmly placing Ondine as a leading supplier of innovative non-antibiotic products addressing the $35-$45 billion per year healthcare-associated infection (HAI) market1. Urinary tract infections (UTIs) are considered to be the largest source of HAIs, representing about 30% of all reported cases, with catheter-associated UTIs representing 75% of this number. Read More
It used to be that cancer was a rare condition; something one saw only in the movies or heard about in books. That is how it used to be when I was growing up in the 1960′s & ’70′s. By the time the ’80′s rolled around, cancer had reached my neighbourhood, but still did not affect me directly. I would hear of the odd case of a school chum’s mother or grandfather dying from this disease. Over the years, however, I would come to hear of more and more people around me having cancer. Read More
Ondine would like to congratulate this year’s Manning Innovation Award winners. Since 1982, the Ernest C. Manning Awards Foundation has been honouring Canadian innovators who have successfully marketed their innovation. These prestigious awards give recognition to outstanding Canadian technologies and their innovators. Read More
“There are two kinds of light — the glow that illumines, and the glare that obscures.”
James Thurber was almost certainly unaware of photodynamic medicine when he authored that quote in 1963, or else he might have added a 3rd type of light – the glimmer that heals. Loosely put, the word photodynamic means using light to cause an action or effect. This definition, though simple, succinctly summarizes the concept of photodynamic medicine – a set of therapies that leverages visible light to create a targeted, potent effect. Read More
1 Comment 
